Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2016
At a glance
- Drugs GRC 15300 (Primary)
- Indications Neuropathic pain
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms ALCHEMILLA
- 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Dec 2012 Planned End Date changed from 1 Mar 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
- 22 Feb 2012 Actual initiation date (Nov 2011) added and additional locations (Czech Republic, Hungary, Multinational, Poland, Russia, Slovakia, Ukraine) added as reported by European Clinical Trials Database.